DXCM DexCom, Inc. logo

DXCM DexCom, Inc.

Healthcare
$72.10+0.28%ClosedMarket Cap: $27.82B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

29.86

PEG

0.66

P/B

9.39

P/S

5.77

EV/EBITDA

21.73

DCF Value

$34.50

FCF Yield

5.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

61.8%

Operating Margin

21.4%

Net Margin

19.3%

ROE

33.8%

ROA

14.0%

ROIC

18.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$1.19B$199.5M$
Q4 null$1.26B$267.3M$
FY null$4.66B$836.3M$
Q3 null$1.21B$283.8M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$78.25

Target (Median)

$78.50

Target Range

$64.00 - $92.00

4 Strong Buy21 Buy3 Hold0 Sell1 Strong Sell
BarclaysUnderweight
2026-05-18
Canaccord GenuityBuy
2026-05-18
B of A SecuritiesBuy
2026-05-18
CitigroupBuy
2026-05-04
TD CowenBuy
2026-05-01

Trading Activity

Insider Trades

View All
Brown Michael Jonofficer: EVP, Chief Legal Officer
SellTue May 19
Heller Bridgette Pdirector
SellThu May 14
FOLETTA MARK Gdirector
SellMon May 11
Collins Richard Alexanderdirector
SellMon May 11
AUGUSTINOS NICHOLASdirector
SellMon May 11

Congress Trades

View All
Ro KhannaBuy
Wed May 13
John BoozmanBuy
Sun Feb 15

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.40

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Peers